Mumbai, Aug. 6 -- Emcure Pharmaceuticals on Thursday reported a 36.2 per cent year-on-year rise in its consolidated profit after tax (PAT) to Rs 292.5 crore for the quarter ended June 30, 2026, while revenue increased 22.8 per cent to Rs 2,580.4 crore.

The company's earnings before interest, tax, depreciation and amortisation (EBITDA) rose 25.8 per cent to Rs 508 crore during the quarter, while EBITDA margin improved by around 50 basis points to 19.7 per cent. PAT margin also expanded by around 110 basis points to 11.3 per cent.

Commenting on the performance, Managing Director and CEO Satish Mehta said, "We have begun FY27, the second year of our five-year plan--on a strong footing. FY26 was about putting the building blocks in place ac...